Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

Recruiting now · Not applicable

Conditions studied: Chest Pain

In brief

This is a randomised controlled trial to determine the effectiveness of Vericiguat to improve stress myocardial blood flow (MBF) and myocardial perfusion reserve as measured by cardiac magnetic resonance (CMR) imaging.

Key facts

Study ID: NCT06239974
Run by: The University of Hong Kong
People needed: 94
Starts: 2024-09-01
Expected to finish: 2027-08-31
Last updated by the study team: 2026-06-29

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Stable recurrent chest pain.
40 to 75 years old.
Have coronary computed tomography (CT) angiogram or catheter coronary angiogram within 6 months showing non-obstructive coronary artery disease (<50% coronary artery stenosis or fractional flow reserve >0.8).
Stress CMR MPR <2.19 12 or Stress MBF <2.19ml/g/min 13.
Female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP),or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 1 month after the last dose of study intervention.

You may not qualify if…

Systolic blood pressure <100 mm Hg.
Concurrent use of soluble guanylate cyclase stimulators (eg. Riociguat), or phosphodiesterase type 5 inhibitors (eg. vardenafil, tadalafil, and sildenafil).
Has known allergy or sensitivity to any soluble guanylate cyclase stimulator.
On long-acting nitrates (eg. isosorbide mononitrate)
Known cardiomyopathy, complex congenital heart disease, endocarditis or pericarditis.
Has acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction (NSTEMI), or ST elevation myocardial infarction (STEMI)) or coronary revascularization (coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)) within 60 days prior to randomisation, or indication for coronary revascularization at time of randomisation.
Has symptomatic carotid stenosis, transient ischemic attack (TIA) or stroke within 60 days prior to randomisation.
Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2
Malignancy or other non-cardiac condition limiting life expectancy to <3 years.
Patient's with implanted devices which are not MRI compatible.

Where it is running

The University of Hong Kong — Hong Kong, Hong Kong (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.